National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Mogamulizumab (Poteligeo®). HTA ID: 20061

Mogamulizumab (Poteligeo®) is indicated for the treatment of adult patients with mycosis fungoides or Sézary syndrome who have received at least one prior systemic therapy.

NCPE Assessment Process Complete
Rapid review commissioned 21/12/2020
Rapid review completed 14/01/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of mogamulizumab (Poteligeo®) compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 27/01/2021
Pre-submission consultation with Applicant 23/03/2021
Full submission received from Applicant 07/10/2021
Preliminary review sent to Applicant 22/02/2022
NCPE assessment re-commenced 22/03/2022
Follow-up to preliminary review sent to Applicant 07/04/2022
NCPE assessment re-commenced 19/04/2022
Factual accuracy check sent to Applicant 17/06/2022
NCPE assessment re-commenced 24/06/2022
NCPE assessment completed
NCPE assessment outcome The NCPE recommends that mogamulizumab (Poteligeo®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.